MedTrace Logo

Seerlinq: Non-invasive LVFP Monitoring in HF

NCT06649435 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 131

Last updated 2025-11-20

No results posted yet for this study

Summary

Left ventricular filling pressure (LVFP) monitoring has been associated with improved quality of life, survival and reduced hospitalization rates. However, current LVFP monitoring methods are invasive, costly, and require long-term antithrombotic therapy.

The purpose of this study is to validate Seerlinq HeartCore, a novel CE-certified, non-invasive system that enables remote LVFP monitoring using photoplethysmography (PPG) and machine learning-based signal analysis.

Conditions

Interventions

PROCEDURE

PPG measurement

PPG signal will be measured on CE certified medical devices. Two measurements will be performed - standing and in the recumbent position using reflectance and transmitance method on finger and in ear canal. The each measurement will be 120s long. Detailed analysis of PPG signal and pathophysiological phenomena associated with HF - peripheral volume changes detectable in PPG signal - will help to understand better and clarify the pathophysiological mechanisms of peripheral volume changes in a failing heart.

Sponsors & Collaborators

  • Premedix Academy

    collaborator OTHER

  • Seerlinq s. r. o.

    lead OTHER

Principal Investigators

  • Allan Böhm, MD · Seerlinq

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2023-12-01
Completion
2024-12-01

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06649435 on ClinicalTrials.gov